Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

BACKGROUND: Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy remains uncertain. METHODS: In the Adjuvant Lapatinib a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Piccart-Gebhart, Martine, Holmes, Eileen, Baselga, José, de Azambuja, Evandro, Dueck, Amylou C., Viale, Giuseppe, Zujewski, Jo Anne, Goldhirsch, Aron, Armour, Alison, Pritchard, Kathleen I., McCullough, Ann E., Dolci, Stella, McFadden, Eleanor, Holmes, Andrew P., Tonghua, Liu, Eidtmann, Holger, Dinh, Phuong, Di Cosimo, Serena, Harbeck, Nadia, Tjulandin, Sergei, Im, Young-Hyuck, Huang, Chiun-Sheng, Diéras, Véronique, Hillman, David W., Wolff, Antonio C., Jackisch, Christian, Lang, Istvan, Untch, Michael, Smith, Ian, Boyle, Frances, Xu, Binghe, Gomez, Henry, Suter, Thomas, Gelber, Richard D., Perez, Edith A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2016
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872016/
https://ncbi.nlm.nih.gov/pubmed/26598744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.1797
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares